AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial-Reference-Cited by-同舟云学术

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Published:2020-08-09 Issue:3 Volume:73 Page:531-534
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Ivashchenko Andrey A¹,Dmitriev Kirill A²,Vostokova Natalia V³,Azarova Valeria N³,Blinow Andrew A⁴,Egorova Alina N³,Gordeev Ivan G⁵,Ilin Alexey P⁶,Karapetian Ruben N⁷,Kravchenko Dmitry V⁶,Lomakin Nikita V⁸,Merkulova Elena A³,Papazova Natalia A⁹,Pavlikova Elena P¹⁰,Savchuk Nikolay P¹¹,Simakina Elena N¹²,Sitdekov Tagir A²,Smolyarchuk Elena A¹³,Tikhomolova Elena G¹⁴,Yakubova Elena V⁴,Ivachtchenko Alexandre V¹¹

Affiliation:

1. ChemRar High-Tech Center, Khimki, Moscow region, Russian Federation

2. Russian Direct Investment Fund, Moscow, Russian Federation

3. IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation

4. Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation

5. City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation

6. Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation

7. Department of Biology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation

8. Central Clinical Hospital with Polyclinic, Moscow, Russian Federation

9. Department of Finished Dosage Forms, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation

10. Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation

11. Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation

12. Clinical Hospital No.1, Smolensk, Russian Federation

13. First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation

14. Infectious clinical hospital No. 2, Nizhny Novgorod, Russian Federation

Abstract

Abstract In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.

Funder

AVIFAVIR

Russian Direct Investment Fund

Trade of the Russian Federation and the Skolkovo Innovation Center

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1176/34459516/ciaa1176.pdf

Reference9 articles.

1. Available evidence and ongoing clinical trials of remdesivir: could it be a promising therapeutic option for COVID-19?;Sisay;Front Pharmacol,2020